Osage University Partners has returned to back a series C1 round for Antiva, which is developing treatments for HPV and is based on research at UC San Diego.

Antiva Biosciences, a US-based human papilloma virus (HPV) therapy developer spun out from University of California (UC) San Diego, raised $15m in a series C1 round yesterday featuring spinout-focused investment firm Osage University Partners.

Hillhouse Capital Management led the round, while Brace Pharma, the investment division of pharmaceutical firm EMS, Sirona Capital, Canaan Partners, Sofinnova Ventures and Lumira Capital also took part.

Founded in 2012, Antiva is developing topical therapeutics for conditions caused by HPV infection. Antiva’s lead candidate, ABI-1968,…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?